Safety considerations in somatic gene therapy of human disease with retrovirus vectors
Somatic gene therapy of human disease with retrovirus vectors is a new technology with potentially important medical benefits. Although it involves recombinant DNA technologies and modified retroviruses, proper design of the vectors and delivery systems removes most potential foreseen risks. Further...
Gespeichert in:
| Veröffentlicht in: | Human gene therapy 1990, Vol.1 (2), p.111-123 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 123 |
|---|---|
| container_issue | 2 |
| container_start_page | 111 |
| container_title | Human gene therapy |
| container_volume | 1 |
| creator | Temin, H M |
| description | Somatic gene therapy of human disease with retrovirus vectors is a new technology with potentially important medical benefits. Although it involves recombinant DNA technologies and modified retroviruses, proper design of the vectors and delivery systems removes most potential foreseen risks. Furthermore, even in the very remote possibility that there is a nontherapeutic biological effect of the treatment, it is unlikely to be a harmful one. Thus, once very safe retrovirus vector-helper cell systems are constructed and in use, safety considerations should not hold up further human trials of retrovirus vectors. |
| doi_str_mv | 10.1089/hum.1990.1.2-111 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80291836</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15747734</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-3ad3e2cff6f0a40905befca4564221fea3b00e8c16d057e06ffde10ef5f1a3503</originalsourceid><addsrcrecordid>eNqFUctOwzAQtBAIyuPOBcknbim7dhwnR1Txkipx4HG1XGdNg5qk2ElR_x5XVFw57Y52Zna1w9glwhShrG6WYzvFqkpoKjJEPGATVEpnOhfiMPWQywxkLk7YaYyfAChVoY_ZsQBdKq0m7P3Fehq23PVdbGoKdmhSx5uOx75NwPEP6ogPyzRab3nveVppO143kWwk_t0MSx5oCP2mCWPkG3JDH-I5O_J2FeliX8_Y2_3d6-wxmz8_PM1u55lLhwyZtLUk4bwvPNgcKlAL8s7mqkj3oycrFwBUOixqUJqg8L4mBPLKo5UK5Bm7_vVdh_5rpDiYtomOVivbUT9GU4KosJTFv0QsEESR_--ISudayzwR4ZfoQh9jIG_WoWlt2BoEswvHpE-ZXTgGjTApnCS52nuPi5bqP8E-DfkDaT6MhA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15747734</pqid></control><display><type>article</type><title>Safety considerations in somatic gene therapy of human disease with retrovirus vectors</title><source>Mary Ann Liebert Online Subscription</source><source>MEDLINE</source><creator>Temin, H M</creator><creatorcontrib>Temin, H M</creatorcontrib><description>Somatic gene therapy of human disease with retrovirus vectors is a new technology with potentially important medical benefits. Although it involves recombinant DNA technologies and modified retroviruses, proper design of the vectors and delivery systems removes most potential foreseen risks. Furthermore, even in the very remote possibility that there is a nontherapeutic biological effect of the treatment, it is unlikely to be a harmful one. Thus, once very safe retrovirus vector-helper cell systems are constructed and in use, safety considerations should not hold up further human trials of retrovirus vectors.</description><identifier>ISSN: 1043-0342</identifier><identifier>EISSN: 1557-7422</identifier><identifier>DOI: 10.1089/hum.1990.1.2-111</identifier><identifier>PMID: 2078575</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; clinical medicine ; cloning vectors ; gene expression ; gene transfer ; Genetic Therapy - economics ; Genetic Therapy - methods ; Genetic Vectors ; genetics ; Humans ; Retroviridae - genetics ; Risk Factors ; Safety ; Socioeconomic Factors ; vectors</subject><ispartof>Human gene therapy, 1990, Vol.1 (2), p.111-123</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-3ad3e2cff6f0a40905befca4564221fea3b00e8c16d057e06ffde10ef5f1a3503</citedby><cites>FETCH-LOGICAL-c356t-3ad3e2cff6f0a40905befca4564221fea3b00e8c16d057e06ffde10ef5f1a3503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3042,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2078575$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Temin, H M</creatorcontrib><title>Safety considerations in somatic gene therapy of human disease with retrovirus vectors</title><title>Human gene therapy</title><addtitle>Hum Gene Ther</addtitle><description>Somatic gene therapy of human disease with retrovirus vectors is a new technology with potentially important medical benefits. Although it involves recombinant DNA technologies and modified retroviruses, proper design of the vectors and delivery systems removes most potential foreseen risks. Furthermore, even in the very remote possibility that there is a nontherapeutic biological effect of the treatment, it is unlikely to be a harmful one. Thus, once very safe retrovirus vector-helper cell systems are constructed and in use, safety considerations should not hold up further human trials of retrovirus vectors.</description><subject>Animals</subject><subject>clinical medicine</subject><subject>cloning vectors</subject><subject>gene expression</subject><subject>gene transfer</subject><subject>Genetic Therapy - economics</subject><subject>Genetic Therapy - methods</subject><subject>Genetic Vectors</subject><subject>genetics</subject><subject>Humans</subject><subject>Retroviridae - genetics</subject><subject>Risk Factors</subject><subject>Safety</subject><subject>Socioeconomic Factors</subject><subject>vectors</subject><issn>1043-0342</issn><issn>1557-7422</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUctOwzAQtBAIyuPOBcknbim7dhwnR1Txkipx4HG1XGdNg5qk2ElR_x5XVFw57Y52Zna1w9glwhShrG6WYzvFqkpoKjJEPGATVEpnOhfiMPWQywxkLk7YaYyfAChVoY_ZsQBdKq0m7P3Fehq23PVdbGoKdmhSx5uOx75NwPEP6ogPyzRab3nveVppO143kWwk_t0MSx5oCP2mCWPkG3JDH-I5O_J2FeliX8_Y2_3d6-wxmz8_PM1u55lLhwyZtLUk4bwvPNgcKlAL8s7mqkj3oycrFwBUOixqUJqg8L4mBPLKo5UK5Bm7_vVdh_5rpDiYtomOVivbUT9GU4KosJTFv0QsEESR_--ISudayzwR4ZfoQh9jIG_WoWlt2BoEswvHpE-ZXTgGjTApnCS52nuPi5bqP8E-DfkDaT6MhA</recordid><startdate>1990</startdate><enddate>1990</enddate><creator>Temin, H M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T3</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7QO</scope><scope>7T2</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>1990</creationdate><title>Safety considerations in somatic gene therapy of human disease with retrovirus vectors</title><author>Temin, H M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-3ad3e2cff6f0a40905befca4564221fea3b00e8c16d057e06ffde10ef5f1a3503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Animals</topic><topic>clinical medicine</topic><topic>cloning vectors</topic><topic>gene expression</topic><topic>gene transfer</topic><topic>Genetic Therapy - economics</topic><topic>Genetic Therapy - methods</topic><topic>Genetic Vectors</topic><topic>genetics</topic><topic>Humans</topic><topic>Retroviridae - genetics</topic><topic>Risk Factors</topic><topic>Safety</topic><topic>Socioeconomic Factors</topic><topic>vectors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Temin, H M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Human Genome Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Biotechnology Research Abstracts</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Human gene therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Temin, H M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety considerations in somatic gene therapy of human disease with retrovirus vectors</atitle><jtitle>Human gene therapy</jtitle><addtitle>Hum Gene Ther</addtitle><date>1990</date><risdate>1990</risdate><volume>1</volume><issue>2</issue><spage>111</spage><epage>123</epage><pages>111-123</pages><issn>1043-0342</issn><eissn>1557-7422</eissn><abstract>Somatic gene therapy of human disease with retrovirus vectors is a new technology with potentially important medical benefits. Although it involves recombinant DNA technologies and modified retroviruses, proper design of the vectors and delivery systems removes most potential foreseen risks. Furthermore, even in the very remote possibility that there is a nontherapeutic biological effect of the treatment, it is unlikely to be a harmful one. Thus, once very safe retrovirus vector-helper cell systems are constructed and in use, safety considerations should not hold up further human trials of retrovirus vectors.</abstract><cop>United States</cop><pmid>2078575</pmid><doi>10.1089/hum.1990.1.2-111</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-0342 |
| ispartof | Human gene therapy, 1990, Vol.1 (2), p.111-123 |
| issn | 1043-0342 1557-7422 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80291836 |
| source | Mary Ann Liebert Online Subscription; MEDLINE |
| subjects | Animals clinical medicine cloning vectors gene expression gene transfer Genetic Therapy - economics Genetic Therapy - methods Genetic Vectors genetics Humans Retroviridae - genetics Risk Factors Safety Socioeconomic Factors vectors |
| title | Safety considerations in somatic gene therapy of human disease with retrovirus vectors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T23%3A56%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20considerations%20in%20somatic%20gene%20therapy%20of%20human%20disease%20with%20retrovirus%20vectors&rft.jtitle=Human%20gene%20therapy&rft.au=Temin,%20H%20M&rft.date=1990&rft.volume=1&rft.issue=2&rft.spage=111&rft.epage=123&rft.pages=111-123&rft.issn=1043-0342&rft.eissn=1557-7422&rft_id=info:doi/10.1089/hum.1990.1.2-111&rft_dat=%3Cproquest_cross%3E15747734%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15747734&rft_id=info:pmid/2078575&rfr_iscdi=true |